Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension [Phase 3]

View source ↗

Summary

Phase 3 trial (KEYNOTE-921) evaluating pembrolizumab with docetaxel versus placebo with docetaxel in chemotherapy-naïve metastatic castration-resistant prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostatic Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2023-08-04